SEARCH

SEARCH BY CITATION

References

  • 1
    Firestein GS (2003) Evolving concepts of rheumatoid arthritis. Nature 423, 35661.
  • 2
    Gabriel SE (2001) The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 27, 26981.
  • 3
    McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365, 220519.
  • 4
    Weinblatt ME, Coblyn JS, Fox DA et al. (1985) Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 312, 81822.
  • 5
    Weinblatt ME (2003) Rheumatoid arthritis in 2003: where are we now with treatment? Ann Rheum Dis 62 (Suppl 2), ii946.
  • 6
    Lipsky PE, van der Heijde DM et al. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343, 1594602.
  • 7
    Singh JA, Furst DE, Bharat A et al. (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 64, 62539.
  • 8
    Blum MA, Koo D, Doshi JA (2011) Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Ther 33, 90113.
  • 9
    Weinblatt ME, Kremer JM, Bankhurst AD et al. (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340, 2539.
  • 10
    Maini R, St Clair EW, Breedveld F et al. (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354, 19329.
  • 11
    Weinblatt ME, Keystone EC, Furst DE et al. (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48 (1), 3545.
  • 12
    Kremer JM, Westhovens R, Leon M et al. (2003) Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349, 190715.
  • 13
    Listing J, Strangfeld A, Rau R et al. (2006) Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low–results from RABBIT, the German biologics register. Arthritis Res Ther 8, R66.
  • 14
    Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298, 191234.
  • 15
    Alten RE, Zerbini C, Jeka S et al. (2010) Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy. Ann Rheum Dis 69, 3647.
  • 16
    Cohen SB, Cheng TT, Chindalore V et al. (2009) Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 60, 33544.
  • 17
    Christodoulou C, Choy EH (2006) Joint inflammation and cytokine inhibition in rheumatoid arthritis. Clin Exp Med 6 (1), 139.
  • 18
    Damjanov N, Kauffman RS, Spencer-Green GT (2009) Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 60, 123241.
  • 19
    Genovese MC, Cohen SB, Wofsy D et al. (2011) A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. J Rheumatol 38, 84654.
  • 20
    Seavey MM, Dobrzanski P (2012) The many faces of Janus kinase. Biochem Pharmacol 83, 113645.
  • 21
    O'Shea JJ, Holland SM, Staudt LM (2013) JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 368, 16170.
  • 22
    van Vollenhoven RF (2013) Small molecular compounds in development for rheumatoid arthritis. Curr Opin Rheumatol 25, 3917.
  • 23
    Luo C, Laaja P (2004) Inhibitors of JAKs/STATs and the kinases: a possible new cluster of drugs. Drug Discov Today 9, 26875.
  • 24
    Casanova JL, Holland SM, Notarangelo LD (2012) Inborn errors of human JAKs and STATs. Immunity 36, 51528.
  • 25
    Kremer JM, Bloom BJ, Breedveld FC et al. (2009) The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 60, 1895905.
  • 26
    Fleischmann R, Cutolo M, Genovese MC et al. (2012) Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 64, 61729.
  • 27
    Kremer JM, Cohen S, Wilkinson BE et al. (2012) A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 64, 97081.
  • 28
    van Vollenhoven RF, Fleischmann R, Cohen S et al. (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367, 50819.
  • 29
    Fleischmann R, Kremer J, Cush J et al. (2012) Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367, 495507.
  • 30
    Burmester GR, Blanco R, Charles-Schoeman C et al. (2013) Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381, 45160.
  • 31
    van der Heijde D, Tanaka Y, Fleischmann R et al. (2013) Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 65, 55970.
  • 32
    Jurgen W, Silverfield JC, Lee EB et al. (2012). ABSTRACT: Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy up to 48 Months. Presented at the American College of Rheumatology Annual Scientific Meeting, Washington, DC.
  • 33
    Mariette X, Curtis JR, Lee EB (2012). ABSTRACT: Tofacitinib (CP-690,550), an oral janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical programme. Presented at the Annual European Congress of Rheumatology; Berlin, Germany.
  • 34
    Charles-Schoeman C, Wicker P, Sechtem U (2012). ABSTRACT: Cardiovascular safety findings in rheumatoid arthritis patients treated with tofacitinib. Presented at the Annual European Congress of Rheumatology; Berlin, Germany.
  • 35
    Quintas-Cardama A, Kantarjian H, Cortes J, Verstovsek S (2011) Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov 10, 12740.
  • 36
    Fridman JS, Scherle PA, Collins R et al. (2010) Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 184, 5298307.
  • 37
    Fleischmann R, Spencer-Green GT, Fan F (2011). Dose ranging study of VX-509, an oral selective JAK3 inhibitor, as monotherapy in patients with active rheumatoid arthritis (RA). Presented at the American College of Rheumatology Annual Meeting, Chicago, IL.
  • 38
    Vanhoutte FPM, Mazur M, Van der Aa A, Wigerinck P, van't Klooster GAE (2012) ABSTRACT: Selective JAK1 Inhibition in the Treatment of Rheumatoid Arthritis: Proof of Concept with GLPG0634. Presented at the American College of Rheumatology Annual Scientific Meeting. Washington, DC.
  • 39
    Vanhoutte FP, Van der Aa A, Meuleners L, van't Klooster GAE (2013) ABSTRACT: Safety and Efficacy of GLPG0634, a Selective JAK1 Inhibitor, in Patients with Rheumatoid Arthritis: Results of a 4-Week Phase IIA Multicenter, Dose Ranging Study. Presented at the Annual European Congress of Rheumatology; Madrid, Spain.
  • 40
    Wong BR, Grossbard EB, Payan DG, Masuda ES (2004) Targeting Syk as a treatment for allergic and autoimmune disorders. Expert Opin Investig Drugs 13, 74362.
  • 41
    Cheng AM, Rowley B, Pao W, Hayday A, Bolen JB, Pawson T (1995) Syk tyrosine kinase required for mouse viability and B-cell development. Nature 378, 3036.
  • 42
    Mocsai A, Humphrey MB, Van Ziffle JA et al. (2004) The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci USA 101, 615863.
  • 43
    Cha HS, Boyle DL, Inoue T et al. (2006) A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther 317, 5718.
  • 44
    Weinblatt ME, Kavanaugh A, Burgos-Vargas R et al. (2008) Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 58, 330918.
  • 45
    Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB (2010) An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 363, 130312.
  • 46
    Genovese MC, Kavanaugh A, Weinblatt ME et al. (2011) An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum 63, 33745.
  • 47
    Weinblatt ME, Kavanaugh A, Genovese MC et al. (2013) Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial. J Rheumatol 40, 36978.
  • 48
    Gallivan R (2013) AstraZeneca to Incur $140M Charge After Fostamatinib Disappointment. The Wall Street Journal. [Cited 4 June 2013.] Available from: http://online.wsj.com/article/BT-CO-20130604-700544.html
  • 49
    Kontzias A, Kotlyar A, Laurence A, Changelian P, O'Shea JJ (2012) Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol 12, 46470.
  • 50
    Leonard WJ (2001) Role of Jak kinases and STATs in cytokine signal transduction. Int J Hematol 73, 2717.